Evidence map›Paper›PMID 36553033›Full record

ArticleDiagnostics (Basel, Switzerland)2022

A Novel

Maryam Eghbali, Sara Cheraghi, Sara Samanian, Iman Rad, Jafar Meghdadi, Hamideh Akbari, Maryam Honardoost

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Maryam EghbaliEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran 1593716615, Iran.
Sara CheraghiEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran 1593716615, Iran.ORCID 0000-0003-2490-2757
Sara SamanianGenetic Foundation of Tehran, Solaleh Diagnostic Laboratory, Tehran 1393845944, Iran.
Iman RadStem Cell Technology Research Center (STRC), Tehran 1665666311, Iran.
Jafar MeghdadiStem Cell Technology Research Center (STRC), Tehran 1665666311, Iran.
Hamideh AkbariClinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan 49178677439, Iran.
Maryam HonardoostEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran 1593716615, Iran.
Iran University of Medical Sciences · IRStem Cell Technology Research Center · IRGolestan University of Medical Sciences · IRIran National Science Foundation · IR

Funding

Iran University of Medical Sciences IR.IUMS.REC.1399.081
6 · The paper itself

Abstract

Background: Primary macronodular adrenocortical hyperplasia (PMAH) is a rare form of adrenal Cushing’s syndrome with incomplete penetrance which may be sporadic or autosomal dominant. The inactivation of the ARMC5 gene, a potential tumor suppressor gene, is one of the associated causes of PMAH. This study aimed to identify the variant responsible for Iranian familial PMAH. Methods: The proband, a 44-year-old woman, was directed to whole-exome sequencing (WES) of the blood sample to discover a germline variant. In addition, the identified causative variant was confirmed and segregated in other and available unaffected family members. Results: The novel germline heterozygous missense variant, c.2105C>A in the ARMC5 gene, was found, and the same germline variant as the proband was confirmed in two affected sisters. This variant was detected in the brother of the proband with an asymptomatic condition and this considered because of incomplete penetrance and age-dependent appearance. The function of the ARMC5 protein would be damaged by the identified variant, according to in silico and computer analyses that followed. Conclusion: The new germline ARMC5 variation (c.2105C>A, (p. Ala702Glu)) was interpreted as a likely pathogenic variant based on ACMG and Sherloc standards. PMAH may be diagnosed early using genetic testing that shows inherited autosomal dominant mutations in the ARMC5 gene.

Indexed as

ARMC5novel germline variantPMAHwhole-exome sequencing

Identifiers

PMID36553033
PMCPMC9777150
OpenAlexW4311522231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.